GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Cardio Diagnostics Holdings CDIO · USD

Health Care · US listing · 🇺🇸 United States

Compare

1.82

+10.30%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Cardio Diagnostics Holdings

From its filings with the US Securities and Exchange Commission

SEC filings

Cardio Diagnostics Holdings is based in Chicago, Illinois and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker CDIO. The SEC classifies its business as in vitro & in vivo diagnostic substances. In the fiscal year to 31 December 2025, it reported revenue of $14,825 and a net loss of $6.5m. At that date it held total assets of $7.8m and shareholders' equity of $7.0m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
23 Nov 2021
Employees
7
Head office
311 W. SUPERIOR STREET, CHICAGO, IL, 60645
Incorporated in
DE
Classification
In Vitro & In Vivo Diagnostic Substances
Filer status
<br>Emerging growth company

Leadership

Pay as last reported

  • Dr. Warren HosseinionNon-Executive Chairman of the Board$375,349
  • Dr. Meeshanthini DoganChief Executive Officer, Director$1.3m
  • Ms. Elisa LuqmanChief Financial Officer$350,349
  • Mr. Timur DoganChief Technology Officer$761,495
  • Dr. Robert PhilibertChief Medical Officer, Director
  • Ms. Wendy BettsIndependent Director$6,250
  • Mr. Paul BurtonIndependent Director$50,000
  • Mr. Peter FungIndependent Director$6,250
  • Mr. James IntraterIndependent Director$50,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Cardio Diagnostics Holdings Inc employs 7 full-time employees in Chicago, Illinois.
  • The company's Epi+Gen CHD and PrecisionCHD tests are categorized as laboratory-developed tests (LDTs).
  • Cardio Diagnostics Holdings Inc provides AI-driven Integrated Genetic-Epigenetic Engine for cardiovascular disease.

Weaknesses

  • The company has only 7 full-time employees in Chicago, Illinois.
  • Cardio Diagnostics Holdings Inc went public on 23 November 2021.
  • The company's products are limited to cardiovascular disease testing.

Opportunities

  • Cardio Diagnostics Holdings Inc serves patients, clinicians, hospitals/health systems, employers and payors.
  • The company's Epi+Gen CHD and PrecisionCHD tests target coronary heart disease events including heart attacks.
  • Cardio Diagnostics Holdings Inc is engaged in the development of AI-driven diagnostic tools.

Threats

  • The company's LDTs do not require FDA clearance or approval.
  • Cardio Diagnostics Holdings Inc has no competitors mentioned in the facts.
  • The company's business is limited to cardiovascular disease testing.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.